Key terms
About DCPH
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. The company was founded by Peter A. Petillo and Daniel L. Flynn in 2003 and is headquartered in Waltham, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest DCPH news
Apr 08
8:40am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Deciphera Pharmaceuticals (DCPH) and Shockwave Medical (SWAV)
Feb 21
6:51am ET
Barclays Keeps Their Sell Rating on Deciphera Pharmaceuticals (DCPH)
Feb 07
8:40am ET
Stifel Nicolaus Remains a Buy on Deciphera Pharmaceuticals (DCPH)
Feb 07
8:31am ET
Buy Rating Reaffirmed for Deciphera Pharmaceuticals on Strong Q4 Performance and Promising Drug Prospects
Feb 07
6:20am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Feb 07
5:19am ET
Deciphera Pharmaceuticals (DCPH) Gets a Sell from Barclays
Feb 07
12:50am ET
Analysts Are Bullish on Top Healthcare Stocks: Deciphera Pharmaceuticals (DCPH), ACADIA Pharmaceuticals (ACAD)
Feb 06
12:45pm ET
Deciphera Pharmaceuticals: Strong Buy Rating on Robust Financials and Promising Pipeline
Feb 06
11:35am ET
Deciphera Pharmaceuticals: Sustained Growth and Market Expansion Drive Buy Rating
Feb 06
7:08am ET
Deciphera sees NDA submission for Vimseltinib in 2Q24
Feb 06
7:08am ET
Deciphera sees NDA submission for Vimseltinib in 2Q24
Feb 06
7:04am ET
Deciphera reports Q4 EPS (54c), consensus (58c)
Jan 22
2:23pm ET
Piper Sandler Remains a Buy on Deciphera Pharmaceuticals (DCPH)
Jan 18
11:23am ET
Deciphera presents long-term follow-up results from INTRIGUE Phase 3 trial
Jan 12
6:37am ET
Deciphera, GENESIS Pharma enter distribution agreement for RIPRETINIB
Jan 11
1:33am ET
Deciphera Pharmaceuticals: A Strong Buy on Impressive Qinlock Sales and Promising Vimseltinib Prospects
No recent press releases are available for DCPH
DCPH Financials
Key terms
Ad Feedback
DCPH Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
DCPH Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range